Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
Office:
Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
Aegle Therapeutics Corporation announced that the FDA has granted Fast Track designation to AGLE-102™ for the treatment of patients with dystrophic epidermolysis bullosa , a rare genetic pediatric skin blistering disorder. AGLE-102 is an extracellular vesicle therapy that delivers proteins, genetic material and regenerative healing factors to diseased and damaged tissue. AGLE-102 will be evaluated in DEB patients in a phase I/IIa trial initiating in 2021. Youway is ready to support customers with Fast Track and other accelerated clinical trials.
Join our newsletter mailing list to never miss an update!
Precision in Pharma Supply Chain Summit Boston
November 16-17, 2026
Boston, MA
SCOPE Supply Chain & Logistics Leadership Summit
March 1-4, 2027
Orlando, FL